Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia

Inclusion Criteria: * Able to provide written informed consent and any other authorizations required by local law (e.g., Protected Health Information \[PHI\]) * Have severe or very severe aplastic anemia, or moderate aplastic anemia with platelet counts that have dropped below 20,000/μl * Have moderate, severe, or very severe aplastic anemia with moderate bleeding during or after a surgical procedure, (including bone marrow biopsy, lumbar puncture, thoracentesis, paracentesis, port placement, dermal biopsy) or minimal mucocutaneous bleeding otherwise noted * Subjects with current or previous exposure to approved medications for the treatment of aplastic anemia will not be excluded; these include but may not be limited to, anti-thymocyte globulin (ATG), cyclosporine, corticosteroids, and G-CSF. Exclusion Criteria: * Have diagnosis of Fanconi anemia * Have infection not adequately responding to appropriate therapy * Have Paroxysmal Nocturnal Hemoglobinuria (PNH) clone size in neutrophils of greater than or equal to 50% * Have known HIV positivity * Have creatinine and/or blood urea nitrogen (BUN) ≥2 times the upper limit of normal * Have serum bilirubin ≥ 1.5 times the upper limit of normal, or ≥4.0 times the upper limit of normal if the patient has been treated with ATG within three weeks of screening. * Have AST and/or ALT ≥ 3 times the upper limit of normal * Have hypersensitivity to eltrombopag or its components * Have chemotherapy given less than or equal to 14 days prior to initiating the study medication. This does not include immunosuppressive agents and growth factor as described above * Are female and are nursing or pregnant or are unwilling to take oral contraceptives or refrain from pregnancy if of childbearing potential * Are unable to understand the investigational nature of the study or give informed consent * Have a history of arterial or venous thrombosis within the last 1 year (excluding those due to indwelling lines) * Have an ECOG performance status of 3 or greater * Have had treatment with Campath within 6 months of entry into the study * Have pre-existing cardiovascular disease (congestive heart failure with New York Heart Association \[NYHA\] grade III/IV), arrhythmia known to increase the risk of thromboembolic events (e.g. atrial fibrillation), unstable angina, or QTc \> 450 msec (QTc 480 msec for subjects with bundle branch block), or myocardial infarction within the preceding 6 months) at study entry * Have had other TPO-R agonists medication in the previous 4 weeks.